Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls (Q38446730)

3 September 2017

Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls (English)

1 reference

3 September 2017

1 reference

4

Hans Wilhelm Doerr

1 reference

3 September 2017

9

Regina Allwinn

1 reference

3 September 2017

3

Imke Wieters

1 reference

3 September 2017

6

Sabine Wicker

1 reference

3 September 2017

Markus Bickel

1

1 reference

3 September 2017

Christin Lassmann

2

1 reference

3 September 2017

Eva Herrmann

5

1 reference

3 September 2017

Hans Reinhard Brodt

7

1 reference

3 September 2017

Christoph Stephan

8

1 reference

3 September 2017

Oliver Jung

10

1 reference

3 September 2017

1 July 2013

1 reference

3 September 2017

1 reference

3 September 2017

14

1 reference

3 September 2017

4

1 reference

3 September 2017

175-181

1 reference

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults

3 September 2017

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Pandemic H1N12009 influenza and HIV: a review of natural history, management and vaccine immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

HIV-infected hospitalized patients with 2009 pandemic influenza A (pH1N1)--United States, spring and summer 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Improved neutralizing antibody response in the second season after a single dose of pandemic (H1N1) 2009 influenza vaccine in HIV-1-positive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

Vitamin D supplementation does not increase immunogenicity of seasonal influenza vaccine in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1404-175

21 January 2018

Identifiers

DOI

10.1310/HCT1404-175

1 reference

3 September 2017

1 reference